Skip to content
MMR Sign In Subscribe
Pharmacy — Supplier News

Aurobindo receives FDA approval for baricitinib tablets

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application baricitinib tablets, 1mg and 2mg.

,   and  Bill Schiffner
1 min read

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application baricitinib tablets, 1mg and 2mg. Aurobindo Pharma’s, baricitinib tablets are an AB-rated generic equivalent to the reference listed drug (RLD),Olumiant  Tablets, manufactured by Eli Lilly and Company.

Baricitinib tablets are indicated for the treatment of Rheumatoid Arthritis.
Baricitinib tablets has an estimated market size of US $367 Million for the twelve months ending May 2024, as per IQVIA.

Related

Latest

H-E-B embodies purposefulness
Opinion

H-E-B embodies purposefulness

During remarks delivered at last month’s FMI Midwinter Executive Conference, Boyan, who is also the association’s chairman, spoke about what motivates the company.

,   and  Jeffrey Woldt
The K-shaped economy’s hidden truths
Opinion

The K-shaped economy’s hidden truths

New research from the Kearney Consumer Institute uncovers some hidden aspects of the trend, which, of course, has serious implications for both mass market retailers and consumer packaged goods companies. 

,   and  CDR